Are preoperative serum CA15-3 levels different in breast cancer subgroups?

Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093 Prat, 2011, Deconstructing the molecular portraits of breast cancer, Molecular oncology, 5, 5, 10.1016/j.molonc.2010.11.003 Park, 2012, Implications of Different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer, Oncology, 82, 180, 10.1159/000336081 Goldhirsch, 2011, Strategies for subtyped of dealing with the diversity of breast cancer–highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011, Ann Oncol, 22, 1736, 10.1093/annonc/mdr304 Cheang, 2009, Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer, J Natl Cancer Inst, 101, 736, 10.1093/jnci/djp082 Duffy, 2017, Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM), European Journal of Cancer, 75, 284, 10.1016/j.ejca.2017.01.017 Harris, 2016, Use of Biomarkers to guide decisions on adjuvant systemic therapy forwomenwith early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol, 34, 1134, 10.1200/JCO.2015.65.2289 Senkus, 2015, Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and followup ESMO Guidelines Committee, Ann Oncol, 26, v8e30 Coates, 2015, Tailoring therapies improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015, Ann Oncol, 26, 1533, 10.1093/annonc/mdv221 Molina, 2005, Tumor markers in breast cancer- European Group on Tumor Markers recommendations, Tumour Biol, 26, 281, 10.1159/000089260 Yerushalmi, 2012, Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome, Ann Oncol, 23, 338, 10.1093/annonc/mdr154 Harris, 2007, American Society of Clinical Oncology 2007 update of recommendations for the use of tumour markers in breast cancer, J Clin Oncol, 25, 5287, 10.1200/JCO.2007.14.2364 Mukhopadhyay, 2011, Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy, Biochim Biophys Acta, 1815, 224 Taylor-Papadimitriou, 1999, MUC1 and cancer, Biochimica et Biophysica Acta, 301, 10.1016/S0925-4439(99)00055-1 Hilkens, 1992, Cell membrane-associated mucins and their adhesion-modulating property, Trends in Biochemical Sciences, 17, 359, 10.1016/0968-0004(92)90315-Z Nisman, 2013, The prognostic significance of LIAISON(R) CA15-3 assay in primary breast cancer, Anticancer Res, 33, 293 Duffy, 2010, CA 15-3: uses and limitation as a biomarker for breast cancer, Clinica Chimica Acta, 411, 1869, 10.1016/j.cca.2010.08.039 Fehm, 2004, Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer, Anticancer Res, 24, 1987 Kabel, 2017, Tumor markers of breast cancer: new prospectives, J Oncol Sciences, 3, 5, 10.1016/j.jons.2017.01.001 Duffy, 2015, Biomarkers in breast cancer: where are we and where are we going?, Adv Clin Chem, 71, 2 Shao, 2015, Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer, PloS One, 10, 10.1371/journal.pone.0133830 Goldhirsh, 2013, Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2013, Ann Oncol, 24, 2206, 10.1093/annonc/mdt303 Sandri, 2012, Prognostic role of CA15.3 in 7942 patients with operable breast cancer, Breast Cancer Res Treat, 132, 317, 10.1007/s10549-011-1863-x Li, 2014, Preoperative CA 15-3 levels predict the prognosis of non metastatic; luminal A breast cancer, J Surg Res, 189, 48, 10.1016/j.jss.2014.02.048 Kos, 2013, Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes, J BUON, 18, 608 Wu, 2014, Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer, The Breast, 23, 88, 10.1016/j.breast.2013.11.003 Hammond, 2010, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, Arch Pathol Lab Med, 134, 907, 10.5858/134.6.907 Tang, 2016, Immunohistochemical surrogates for molecular classification of breast carcinoma. A 2015 Update, Arch Pathol Lab Med, 140, 806, 10.5858/arpa.2015-0133-RA Petrelli, 2015, Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients, Breast Cancer Res Treat, 153, 477, 10.1007/s10549-015-3559-0 Dowsett, 2011, Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group, J Natl Cancer Inst, 103, 1656, 10.1093/jnci/djr393 Martin, 2006, Prognostic value of pre-operative serum CA 15-3 levels in breast cancer, Anticancer Res, 26, 3965 Rakha, 2005, Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer, Mod. Pathol., 18, 1295, 10.1038/modpathol.3800445